May increase exposure of P-gp, breast cancer resistance protein (BRCP), organic anion-transporting polypeptide (OATP) 1B1 & OATP1B3 substrates; tenofovir. Increase conc of digoxin, rosuvastatin. Decreased plasma conc w/ potent P-gp or CYP2B6, CYP2C8, CYP3A4 (eg, rifampicin, rifabutin, St. John's wort, carbamazepine, phenobarb & phenytoin) inducers; moderate P-gp or CYP inducers (eg, oxcarbazepine, modafinil or efavirenz). Increased plasma conc w/ P-gp or BCRP inhibitors. Increased plasma conc w/ OATP, CYP2B6, CYP2C8, or CYP3A4 inhibitors. Decreased conc w/ acid reducing agents; efavirenz/emtricitabine/tenofovir disoproxil fumarate. May decrease AUC & Cmax
w/ proton pump inhibitors (omeprazole, lasoprazole, rabeprazole, pantoprazole, esomeprazole). May increase conc of digoxin & rosuvastatin. Reduce therapeutic effect w/ rifapentine. Statins.